Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Rhea-AI Summary

Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the Emerging Growth Virtual Conference scheduled for December 4-5, 2024. The company will present on December 5, 2024, from 12:00 to 12:30 p.m. ET.

The presentation will be accessible through the company's website under the 'Events and Presentations' section, with the webcast replay available for 180 days following the conference. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the event.

MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place December 4-5, 2024.

Details for the Company’s presentation:

Date:	December 5, 2024
Time:	12:00 – 12:30 p.m. ET

The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.

Questions may be submitted in advance to Questions@EmergingGrowth.com or asked during the event.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B^TM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com

FAQ

When is Longeveron (LGVN) presenting at the Emerging Growth Virtual Conference?

Longeveron (LGVN) is presenting on December 5, 2024, from 12:00 to 12:30 p.m. ET at the Emerging Growth Virtual Conference.

How can investors access Longeveron's (LGVN) presentation at the December 2024 Emerging Growth Conference?

Investors can access the presentation through the 'Events and Presentations' section of Longeveron's website, with replay available for 180 days after the conference.

How can investors submit questions for Longeveron's (LGVN) December 2024 conference presentation?

Investors can submit questions in advance to Questions@EmergingGrowth.com or ask them during the live event.

What type of company is Longeveron (LGVN)?

Longeveron (LGVN) is a clinical stage regenerative medicine biotechnology company that develops cellular therapies for life-threatening and chronic aging-related conditions.